HUTCHMED (China) Limited (HK:0013) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
HUTCHMED (China) Limited has appointed Cavendish Capital Markets Limited as a joint corporate broker in London, effective January 1, 2025. This move, alongside continuing partnerships with Panmure Liberum Limited and HSBC Bank plc, reflects HUTCHMED’s strategic efforts to strengthen its financial market presence. The biopharmaceutical company focuses on developing and commercializing therapies for cancer and immunological diseases.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
